[HTML][HTML] Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study
MS Khodadoust, AH Rook, P Porcu, F Foss… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
MS Khodadoust, AH Rook, P Porcu, F Foss, AJ Moskowitz, A Shustov, S Shanbhag, L Sokol…
Journal of Clinical Oncology, 2020•ncbi.nlm.nih.govPembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A
Multicenter Phase II Study - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC6943974
Other Formats PDF (1018K) Actions Cite Collections Share Permalink Copy RESOURCES
Similar articles Cited by other articles Links to NCBI Databases Journal List J Clin Oncol …
Multicenter Phase II Study - PMC Back to Top Skip to main content NIH NLM Logo Access keys
NCBI Homepage MyNCBI Homepage Main Content Main Navigation Search PMC Full-Text
Archive Search in PMC Advanced Search User Guide Journal List J Clin Oncol PMC6943974
Other Formats PDF (1018K) Actions Cite Collections Share Permalink Copy RESOURCES
Similar articles Cited by other articles Links to NCBI Databases Journal List J Clin Oncol …
Abstract
PURPOSE
To assess the efficacy of pembrolizumab in patients with advanced relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS).
ncbi.nlm.nih.gov
